ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio Corporation today announced that the company will present new data demonstrating positive pre-clinical results for its intramuscular (IM) respiratory syncytial virus (RSV) vaccine at the National Foundation for Infectious Diseases (NFID) 16th Annual Conference on Vaccine Research (ACVR). The new research shows that NanoBio’s intramuscular nanoemulsion-adjuvanted respiratory syncytial virus (NE-RSV) vaccine, derived from the company’s novel NanoStat® Technology, was safe and highly effective in protecting cotton rats against RSV without causing enhanced disease. NFID 2013 will take place April 22-24, 2013 in Baltimore, MD.
“RSV is a significant cause of respiratory illness in young children and elderly persons, but to date, no commercially available vaccine exists,” said Ali Fattom, NanoBio’s Senior Vice President of Vaccine Research. “While data supporting the use of the NanoStat technology as an intranasal adjuvant has been previously reported for several vaccines, recent studies, including those being presented this week at NFID, demonstrate the potential benefit of the technology as an intramuscular adjuvant. Because an RSV vaccine would mark a major step forward in the prevention of pediatric hospitalizations, future clinical development of the NanoStat IM adjuvant in RSV and other diseases is being planned.”
NanoBio will present pre-clinical data from “A Novel Intramuscular W805EC Nanoemulsion Adjuvanted Respiratory Syncytial Virus Vaccine Protects Cotton Rats against RSV Challenge” study at NFID on Wednesday, April 24, 2013 at 8:00 am ET in Constellation Ballroom, Salon B. During the presentation, NanoBio will share cotton rat data demonstrating that its intramuscular NanoStat-adjuvanted RSV vaccine:
- Was safe and highly immunogenic;
- Generated high-quality antibodies that were more functional than those generated by formalin-inactivated RSV vaccine with alum;
- Elicited cytokines representative of a balanced Th1/Th2 immune response;
- And protected animals from challenge while causing no histopathology.
Respiratory syncytial virus (RSV) is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. It is the number one cause of childhood hospitalization both in the United States and around the world. Nearly all children are infected with the virus at least once by the age of 2-3 years. The disease is particularly dangerous for premature babies, children with other health conditions and the elderly. Many children develop pulmonary disease and/or asthma from RSV that persists throughout adult life making them susceptible to re-infection. Currently, there are no approved vaccines for RSV, despite tremendous need and widespread interest to develop new therapies.
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat® technology platform. The company’s lead product candidates are treatments for herpes labialis, onychomycosis, vaginitis, cystic fibrosis and a broad platform of intranasal and intramuscular vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan. For more information on NanoBio or its products, please visit http://nanobio.com/index.html.